These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7881640)

  • 1. High-dose interleukin-2 two days a week for metastatic renal cell carcinoma: a FNCLCC multicenter study.
    Escudier B; Ravaud A; Fabbro M; Douillard JY; Négrier S; Chevreau C; Mignot L; Baume D; Dorval T; Vignal F
    J Immunother Emphasis Tumor Immunol; 1994 Nov; 16(4):306-12. PubMed ID: 7881640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
    Thompson JA; Shulman KL; Benyunes MC; Lindgren CG; Collins C; Lange PH; Bush WH; Benz LA; Fefer A
    J Clin Oncol; 1992 Jun; 10(6):960-8. PubMed ID: 1588376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: a phase II trial of the National Biotherapy Study Group.
    Dillman RO; Wiemann MC; Bury MJ; Church C; DePriest C
    Cancer Biother Radiopharm; 1997 Feb; 12(1):5-11. PubMed ID: 10851441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma.
    Escudier B; Farace F; Angevin E; Triebel F; Antoun S; Leclercq B; Brandely M; Aboudaram A; Nitenberg G; Hercend T
    Eur J Cancer; 1993; 29A(5):724-8. PubMed ID: 8471331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer.
    Kruit WH; Goey SH; Lamers CH; Gratama JW; Visser B; Schmitz PI; Eggermont AM; Bolhuis RL; Stoter G
    J Immunother; 1997 Jul; 20(4):312-20. PubMed ID: 9220321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
    Shulman KL; Stadler WM; Vogelzang NJ
    Urology; 1996 Feb; 47(2):194-7. PubMed ID: 8607232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
    Fyfe G; Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Louie AC
    J Clin Oncol; 1995 Mar; 13(3):688-96. PubMed ID: 7884429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2.
    Wang JC; Walle A; Novogrodsky A; Suthanthiran M; Silver RT; Bander NH; Rubin AL; Stenzel KH
    J Clin Oncol; 1989 Dec; 7(12):1885-91. PubMed ID: 2555451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.
    Yang JC; Topalian SL; Parkinson D; Schwartzentruber DJ; Weber JS; Ettinghausen SE; White DE; Steinberg SM; Cole DJ; Kim HI
    J Clin Oncol; 1994 Aug; 12(8):1572-6. PubMed ID: 8040669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.
    Figlin RA; Thompson JA; Bukowski RM; Vogelzang NJ; Novick AC; Lange P; Steinberg GD; Belldegrun AS
    J Clin Oncol; 1999 Aug; 17(8):2521-9. PubMed ID: 10561318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
    Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
    Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive regimen of cytokines with interleukin-2 and interferon alfa-2b in selected patients with metastatic renal carcinoma.
    Négrier S; Mercatello A; Bret M; Merrouche Y; Coronel B; Favrot M; Gaspard M; Dorez D; Philip I; Lanier F
    J Immunother Emphasis Tumor Immunol; 1995 Jan; 17(1):62-8. PubMed ID: 7728307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
    Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
    J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
    Yang JC; Rosenberg SA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S79-84. PubMed ID: 9457400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
    J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
    Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
    Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.